高危前列腺癌常规与低分次放疗:IMRT与3D-CRT毒性和疗效事后分析
PCS-5是一项在高危前列腺癌中比较常规分次放疗(CFRT)与大分割放疗(HFRT)的III期随机试验,本事后分析纳入296例患者,评估IMRT与3D-CRT的疗效及泌尿生殖(GU)和胃肠道(GI)毒性差异。结果显示IMRT较3D-CRT降低急性和迟发性G2+ GI毒性,但急性G1+ GU毒性略增,生化失败无生存、无远处转移生存和总生存无显著差异。
要点
- IMRT较3D-CRT降低急性G2+ GI毒性(OR 0.50)和迟发G2+ GI毒性(OR 0.36)。
- IMRT组急性G1+ GU毒性增加(OR 1.77)。
- 两种技术的生化失败无生存、无远处转移生存和总生存无显著差异。
核心结论
- 在高危前列腺癌接受外照射放疗时,HFRT是标准治疗;本非随机比较中IMRT与更低的急性和迟发G2+ GI毒性相关,急性G1+ GU毒性略增,疗效无差异,IMRT似为优选技术。
研究设计与样本
- PCS-5为III期随机对照试验,1:1随机接受CFRT(76 Gy/38次)或HFRT(68 Gy/25次),全部患者接受长期雄激素抑制(中位24个月)和盆腔放疗。
- 本分析为事后分析,329例中296例纳入,比较IMRT与3D-CRT的毒性和疗效。
- 急性毒性定义为放疗后≤180天,迟发毒性为>180天,采用CTCAE v4评估。
主要发现
- IMRT较3D-CRT降低急性G2+ GI毒性(OR 0.50;95% CI,0.29-0.91;p = 0.023)。
- IMRT较3D-CRT降低迟发G2+ GI毒性(OR 0.36;95% CI,0.16-0.82;p = 0.015)。
- IMRT较3D-CRT增加急性G1+ GU毒性(OR 1.77;95% CI,1.07-2.95;p = 0.03)。
- 生化失败无生存、无远处转移生存和总生存在两技术间无显著差异。
关键数值与推荐
- CFRT剂量为76 Gy分38次,HFRT剂量为68 Gy分25次。
- 毒性分析采用多变量logistic回归校正临床因素,疗效分析采用Cox比例风险回归模型。
临床怎么用
- 在高危前列腺癌外照射放疗中可优先考虑IMRT以降低G2+ GI毒性,同时注意急性G1+ GU毒性可能略增。
局限性
- IMRT与3D-CRT的比较为非随机比较,结论受此局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate Cancer Study 5 (PCS-5) is a phase III, randomized controlled trial comparing conventionally fractionated radiotherapy (CFRT) vs. hypofractionated radiotherapy (HFRT) exclusively in patients with high-risk prostate cancer (PCa). This post hoc analysis evaluates differences in efficacy outcomes as well as genitourinary (GU) and gastrointestinal (GI) toxicities between intensity-modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3D-CRT). MATERIALS AND METHODS: PCS-5 randomized patients in a 1:1 ratio to CFRT (76 Gy in 38 fractions) or HFRT (68 Gy in 25 fractions). All patients received long-term androgen suppression (median duration: 24 months) and pelvic radiation therapy (RT). Acute toxicities were defined as ≤ 180 days post-RT, and delayed toxicities > 180 days using CTCAE v4. Multivariable logistic regression analyses were performed for acute and delayed toxicities, adjusting for clinical factors. Efficacy analyses utilized Cox proportional hazards regression models. RESULTS: Among 329 patients, 296 were included in this study. IMRT reduced acute G2 + GI toxicities (OR 0.50; 95% CI, 0.29-0.91; p = 0.023), delayed G2 + GI toxicities (OR 0.36; 95% CI, 0.16-0.82; p = 0.015), and increased acute G1 + GU toxicities (OR 1.77; 95% CI, 1.07-2.95; p = 0.03) compared to 3D-CRT. Biochemical failure-free survival, distant metastasis-free survival, and overall survival did not significantly differ between techniques. CONCLUSION: In PCS-5, HFRT is a standard treatment for high-risk PCa receiving external beam RT. In this post hoc analysis, IMRT was associated with lower acute and delayed G2 + GI toxicity than 3D-CRT, with a modest increase in acute G1 + GU toxicity and no differences in efficacy. Within the limitations of this non-randomized comparison, IMRT appears to be the preferred technique.
引用
- Martínez C, Tisseverasinghe S, Karim MU, et al. Conventional vs. hypofractionated radiotherapy for high-risk prostate cancer (PCS5), randomized, non-inferiority, phase III trial: Post hoc analysis of radiation therapy toxicities and efficacy of IMRT compared to 3D-CRT. Radiother Oncol. 2026. PMID: 41905637. doi:10.1016/j.radonc.2026.111490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。